LAUSR

Contrast-associated nephropathy (CAN) is an extensively studied but equally controversial sequela of intravascular contrast use. Despite this, there is still significant debate about its definition and thus incidence, the impact of route of contrast administration, and ultimately, what constitutes appropriate clinical practice in light of risks. While guidelines cannot replace clinical judgment, without consensus either enthusiastic withholding of contrast from necessary procedures or its administration despite increased risk may be deleterious to patient outcomes. This article reviews current literature on route-dependent risk and other interplaying factors impacting incidence of CAN.
.